The dormancy strongly associated with ER+ breast cancer (153–155) is one reflection of these types of events, as is the response reported to some therapeutic regimens that include an inhibitor of enzymes that induce and maintain epigenetic modifications (156, 157). Here, ESR1 is linked to breast carcinoma.